
Researchers employed a gas chromatography-mass spectrometry (GC–MS)-based metabolomic approach combined with sophisticated statistical methods to identify metabolic biomarkers in coronary heart disease (CHD), hypertension-comorbid CHD, depression-comorbid CHD, and type 2 diabetes mellitus (T2DM)-comorbid CHD to provide an objective diagnostic method and help identify metabolomic signatures to better identify risk groups early, as well as improve understanding of pathophysiologic pathways.






























